<DOC>
	<DOCNO>NCT02046304</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose gemcitabine give radiotherapy surgery treat sarcoma . This study also look well treatment control sarcoma .</brief_summary>
	<brief_title>PP-Gemcitabine &amp; External Beam Radiation-Sarcomas</brief_title>
	<detailed_description>Before start treatment , participant physical exam , blood test , MRI scan , chest x-ray . A PET scan may do thought necessary . Participants receive drug gemcitabine vein along radiation therapy Days 1 , 8 , 22 , 29 , 43 , 50 . Radiation treatment give 5 day week 5 week . The gemcitabine radiotherapy give outpatient basis . Chemotherapy and/or radiotherapy may stop side effect become severe . About 4 6 week final dose gemcitabine , surgery do remove tumor remove previous surgical scar leftover tumor . During combined treatment , participant see weekly doctor charge radiotherapy study nurse . Blood test do every week treatment . A MRI scan chest x-ray do within 14 day surgery . A PET scan do thought necessary . After surgery do , participant return M. D. Anderson follow-up visit every 4 month first 2 year , every 6 month 3 year , yearly . An ultrasound MRI scan ( extremity trunk ) do 3 month completion treatment . Ultrasound scan perform visit . A MRI scan do later visit need . This investigational study . Gemcitabine approve use FDA . Its use together radiation therapy study experimental . About 36 individual take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Patients cytologic histologic proof Grade II III resectable soft tissue sarcoma extremity trunk . 2 . Patients measurable nonmeasurable disease . Patients S/P prereferral excision eligible . 3 . Inclusion patient prior history malignancy discretion Study Chairman . 4 . Patients must Zubrod Point Scale 0 1 . 5 . Absolute neutrophil count must &gt; 1,500 cells/mm ; platelet count great equal 100,000 platelets/ml ; serum creatinine less equal 1.8 mg/dl , serum glutamate oxaloacetate transaminase ( SGOT ) /serum glutamate pyruvate transaminase ( SGPT ) less equal 3 x normal , total bilirubin less equal 1.5 mg/dl . 6 . Patients must uncontrolled coexist medical condition . 7 . Women childbearing potential must pregnant breast feeding must practice adequate contraception . 8 . All patient must sign informed consent . 1 ) Patients history prior radiotherapy area primary tumor anticipate radiation field would include perineum , scrotum , vaginal introitus eligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Soft Tissue Sarcomas</keyword>
	<keyword>STS</keyword>
	<keyword>Extremity Trunk</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>External beam radiation therapy</keyword>
	<keyword>EBRT</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>XRT</keyword>
</DOC>